Orthofix Medical (OFIX)
(Delayed Data from NSDQ)
$13.09 USD
+0.10 (0.77%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $13.07 -0.02 (-0.15%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.09 USD
+0.10 (0.77%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $13.07 -0.02 (-0.15%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
STERIS (STE) Gains on New Orders, FX Impact Dents Growth
by Zacks Equity Research
STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.
Medtronic (MDT) Enrolls 1st Patient Trial for Hugo RAS System
by Zacks Equity Research
Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.
Syneos Health (SYNH) to Enhance Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) owing to strong international growth.
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
by Zacks Equity Research
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise
by Zacks Equity Research
IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.
Hologic's (HOLX) Panther Utilization Rises, Supply Issue Ails
by Zacks Equity Research
Hologic (HOLX) registers procedural volumes return in GYN Surgical as well as acceleration from its new business lines.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) led by strategic collaborations and noteworthy product launches.
Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
by Zacks Equity Research
With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.
Thermo Fisher (TMO) Expands Global Footprint With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility in China is a strategic addition to the company's global pharma services network.
Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Soars 5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Orthofix (OFIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of -155.56% and 1.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. (JYNT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -125% and 1.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus
by Riya Anand
Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.
Wall Street Analysts Believe Orthofix (OFIX) Could Rally 47%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 46.7% upside potential for Orthofix (OFIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Orthofix (OFIX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 107.69% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of -23.08% and -0.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants
by Zacks Equity Research
Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.
3 Promising MedTech Stocks to Snap Up in Second-Half 2021
by Trina Mukherjee
Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space
by Debanjana Dey
OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.